Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines

References

• Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol. 2011;29(11):1400–7.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29(11):1408–14.
   PubMed Web of Science ®Google Scholar
• Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465–72.
   PubMed Web of Science ®Google Scholar
• Saunders WS, Shuster M, Huang X, Gharaibeh B, Enyenihi AH, Petersen I, et al. Chromosomal instability and cytoskeletal defects in oral cancer cells. Proc Natl Acad Sci USA. 2000;97(1):303–8.
   PubMed Web of Science ®Google Scholar
• Rutkowski S, Cohen B, Finlay J, Luksch R, Ridola V, Valteau-Couanet D, et al. Review medulloblastoma in young children. Pediatr Blood Cancer. 2010;54(4):635–7.
   PubMed Web of Science ®Google Scholar
• Packer RJ. Risk stratification of medulloblastoma: a paradigm for future childhood brain tumor management strategies. Curr Neurol Neurosci Rep. 2011;11(2):124–6.
   PubMed Web of Science ®Google Scholar
• Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4(11):842–54.
   PubMed Web of Science ®Google Scholar
• Montembault E, Prigent C. Aurora kinase: therapeutic potential. Drugs Future. 2005;30(1):1–9.
   Google Scholar
• Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008;14(6):1639–48.
   PubMed Web of Science ®Google Scholar
• Mountzios G, Terpos E, Dimopoulos MA. Aurora kinases as targets for cancer therapy. Cancer Treat Rev. 2008;34(2):175–82.
   PubMed Web of Science ®Google Scholar
• Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009;14(8):780–93.
   PubMed Web of Science ®Google Scholar
• Green MR, Woolery JE, Mahadevan D. Update on aurora kinase targeted therapeutics in oncology. Expert Opin Drug Discov. 2011;6(3):291–307.
   PubMed Web of Science ®Google Scholar
• Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 1998;20(2):189–93.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res. 1999;59(9):2041–4.
   PubMed Web of Science ®Google Scholar
• Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res. 2000;6(5):1833–9.
   PubMed Web of Science ®Google Scholar
• Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res. 2003;9(4):1420–6.
   PubMed Web of Science ®Google Scholar
• Scrideli CA, Carlotti CG Jr, Okamoto OK, Andrade VS, Cortez MA, Motta FJ, et al. Gene expression profile analysis of primary glioblastomas and Non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol. 2008;88(3):281–91.
   PubMed Web of Science ®Google Scholar
• Borges KS, Moreno DA, Martinelli CE Jr, Antonini SR, de Castro M, Tucci S Jr, Neder L, Ramalho LN, Seidinger AL, Cardinalli I, Mastellaro MJ, Yunes JA, Brandalise SR, Tone LG, Scrideli CA. Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): Overexpression of Aurora kinases A and B is associated with a poor prognosis. Pediatr Blood Cancer. 2013;60(11):1809–16.
   PubMed Web of Science ®Google Scholar
• Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, et al. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010;70(23):9846–54.
   PubMed Web of Science ®Google Scholar
• Huang L, Be X, Berry L, Moore E, Janosky B, Wells M, et al. In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases. Xenobiotica. 2011;41(5):400–8.
   PubMed Web of Science ®Google Scholar
• VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV. The aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther. 2009;8(4):930–9.
   PubMed Web of Science ®Google Scholar
• Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, et al. Evaluation of an actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget. 2010;1(7):639–50.
   PubMed Web of Science ®Google Scholar
• Kretzner L, Scuto A, Dino PM, Kowolik CM, Wu J, Ventura P, et al. Combining histone deacetylase inhibitor vorinostat with repression of c-Myc, hTERT, and microRNA levels aurora kinase inhibitors enhances lymphoma cell killing. Cancer Res. 2011;71(11):3912–20.
   PubMed Web of Science ®Google Scholar
• Paller CJ, Wissing MD, Mendonca J, Sharma A, Kim E, Kim HS, et al. Combining the pan-aurora kinase inhibitor AMG900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Med. 2014;3(5):1322–35.
   PubMed Web of Science ®Google Scholar
• Okabe S, Tauchi T, Tanaka Y, Kimura S, Maekawa T, Ohyashiki K. Activity of histone deacetylase inhibitors and an aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: combination of HDAC and aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int. 2013;13(1):32.
   PubMedGoogle Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discovery. 2006;5(9):769–84.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, et al. Cotreatment with vorinostat enhances activity of MK-0457(VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res. 2008;14(19):6106–15.
   PubMed Web of Science ®Google Scholar
• Muscal JA, Scorsone KA, Zhang L, Ecsedy JA, Berg SL. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs. 2013;31(1):39–45.
   PubMed Web of Science ®Google Scholar
• Chen M, Huang J, Yang X, Liu B, Zhang W, Huang L, et al. Serum starvation induced cell cycle synchronization facilitates human somatic cells reprogramming. PLoS One. 2012;7(4):e28203.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.
   PubMed Web of Science ®Google Scholar
• Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol. 2007;4(5):295–304.
   PubMedGoogle Scholar
• Gulino A, Arcella A, Giangaspero F. Pathological and molecular heterogeneity of medulloblastoma. Curr Opin Oncol. 2008;20(6):668–75.
   PubMed Web of Science ®Google Scholar
• Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A. Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res. 2008;14(4):971–6.
   PubMed Web of Science ®Google Scholar
• Lok W, Klein RQ, Saif MW. Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs. 2010;21(4):339–50.
   PubMed Web of Science ®Google Scholar
• Petersen W, Liu J, Yuan L, Zhang H, Schneiderjan M, Cho YJ, et al. Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283. Cancer Lett. 2014;354(1):68–76.
   PubMed Web of Science ®Google Scholar
• Harris PS, Venkataraman S, Alimova I, Birks DK, Balakrishnan I, Cristiano B, et al. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol Cancer. 2014;13:72.
   PubMed Web of Science ®Google Scholar
• Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res. 2004;64(9):3103–11.
   PubMed Web of Science ®Google Scholar
• Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, Yeung SC, Lee MH. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer. 2010;9:42.
   PubMed Web of Science ®Google Scholar
• Lin ZZ, Hsu HC, Hsu CH, Yeh PY, Huang CY, Huang YF, Chen TJ, Kuo SH, Hsu C, Hu FC, Jeng YM, Chung Y, Cheng AL. The Aurora kinase inhibitor VE-465 has anticancer effects in preclinical studies of human hepatocellular carcinoma. J Hepatol. 2009;50:518–27.
   PubMed Web of Science ®Google Scholar
• Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig S, Vallet S, Pozzi S, Patel K, Unitt C, Squires M, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje N. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011;17:3259–71.
   PubMed Web of Science ®Google Scholar
• Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res. 2006;66(15):7668–77.
   PubMed Web of Science ®Google Scholar
• Pirker C, Lötsch D, Spiegl-Kreinecker S, Jantscher F, Sutterlüty H, Micksche M, et al. Response of experimental malignant melanoma models to the pan-aurora kinase inhibitor VE-465. Exp Dermatol. 2010;19(12):1040–7.
   PubMed Web of Science ®Google Scholar
• Bosotti R, Carpinelli P, Healy S, Locatelli G, Cappella P, Lanfrancone L, et al. Transcriptional analysis of the aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells. Gene. 2012;494(2):202–8.
   PubMed Web of Science ®Google Scholar
• Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Treat Res. 2013;141(3):397–408.
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen S, Venditti CA, Pei XY, Nguyen TK, Dent P, et al. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenousleukemia cells sensitive and resistant to imatinib mesylate. Blood. 2008;112(3):793–804.
   PubMed Web of Science ®Google Scholar